Literature DB >> 8600306

Trophic and protective effects of growth/differentiation factor 5, a member of the transforming growth factor-beta superfamily, on midbrain dopaminergic neurons.

K Krieglstein1, C Suter-Crazzolara, G Hötten, J Pohl, K Unsicker.   

Abstract

Growth/differentiation factor 5 (GDF5) is a novel member of the transforming growth factor-beta (TGF-beta) superfamily of multifunctional cytokines. We show here that GDF5 is expresed in the developing CNS including the mesencephalon and acts as a neurotrophic, survival promoting molecule for rat dopaminergic midbrain neurons, which degenerate in Parkinson's disease. Recombinant human GDF5 supports dopaminergic neurons, dissected at embryonic day (E) 14 and cultured for 8 days under serum-free conditions, to almost the same extent as TGF-beta 3, and is as effective as glial cell line-derived neurotrophic factor (GDNF), two established trophic factors for midbrain dopaminergic neurons. In contrast to TGF-beta and GDNF, GDF5 augments numbers of astroglial cells in the cultures, suggesting that it may act indirectly and through pathways different from those triggered by TGF-beta and GDNF. GDF5 also protects dopaminergic neurons against the toxicity of N-methylpyridinium ion (MPP+), which selectively damages dopaminergic neurons through mechanisms currently debated in the etiology of Parkinson's disease (PD). GDF5 may therefore now be tested in animal models of PD and might become useful in the treatment of PD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8600306     DOI: 10.1002/jnr.490420516

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  22 in total

1.  Effects of GDF5 overexpression on embryonic rat dopaminergic neurones in vitro and in vivo.

Authors:  David B O'Sullivan; Patrick T Harrison; Aideen M Sullivan
Journal:  J Neural Transm (Vienna)       Date:  2010-03-27       Impact factor: 3.575

2.  Canonical BMP-Smad signalling promotes neurite growth in rat midbrain dopaminergic neurons.

Authors:  Shane V Hegarty; Louise M Collins; Aisling M Gavin; Sarah L Roche; Sean L Wyatt; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Neuromolecular Med       Date:  2014-03-29       Impact factor: 3.843

Review 3.  Strategies to unravel molecular codes essential for the development of meso-diencephalic dopaminergic neurons.

Authors:  F M J Jacobs; S M Smits; K J M Hornman; J P H Burbach; M P Smidt
Journal:  J Physiol       Date:  2006-06-29       Impact factor: 5.182

Review 4.  Nerve growth factor modulation of the cavernous nerve response to injury.

Authors:  Anthony J Bella; Guiting Lin; Ching-Shwun Lin; Duane R Hickling; Christopher Morash; Tom F Lue
Journal:  J Sex Med       Date:  2009-03       Impact factor: 3.802

Review 5.  Roles for the TGFβ superfamily in the development and survival of midbrain dopaminergic neurons.

Authors:  Shane V Hegarty; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2014-02-07       Impact factor: 5.590

Review 6.  The role of growth/differentiation factor 5 (GDF5) in the induction and survival of midbrain dopaminergic neurones: relevance to Parkinson's disease treatment.

Authors:  Aideen M Sullivan; Gerard W O'Keeffe
Journal:  J Anat       Date:  2005-09       Impact factor: 2.610

Review 7.  TGF-β Family Signaling in Neural and Neuronal Differentiation, Development, and Function.

Authors:  Emily A Meyers; John A Kessler
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-08-01       Impact factor: 10.005

Review 8.  Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations.

Authors:  R G Thorne; W H Frey
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

9.  Neurotrophic effects of growth/differentiation factor 5 in a neuronal cell line.

Authors:  André Toulouse; Grace C Collins; Aideen M Sullivan
Journal:  Neurotox Res       Date:  2011-08-20       Impact factor: 3.911

Review 10.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.